Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BTGGF NASDAQ:MEDP NASDAQ:NRC NASDAQ:SRNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTGGFBitcoin Group$63.22$63.22$63.22▼$63.22$24.43B0.26279 shsN/AMEDPMedpace$314.83+0.7%$306.78$250.05▼$459.77$8.99B1.47379,165 shs324,337 shsNRCNational Research$14.95-1.0%$15.25$9.76▼$27.07$344.06M0.4589,612 shs113,731 shsSRNESorrento Therapeutics$0.01+592.9%$0.00$0.00▼$0.02$5.35M0.9894,535 shs319,185 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTGGFBitcoin Group0.00%0.00%0.00%0.00%+3.36%MEDPMedpace-2.39%-3.04%+4.85%+5.47%-29.65%NRCNational Research-1.82%-10.49%-5.86%+43.40%-35.72%SRNESorrento Therapeutics+7.69%0.00%-33.33%+40.00%-86.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTGGFBitcoin GroupN/AN/AN/AN/AN/AN/AN/AN/AMEDPMedpace3.736 of 5 stars1.11.00.04.62.24.22.5NRCNational Research2.1419 of 5 stars0.04.01.70.01.32.51.3SRNESorrento Therapeutics0.36 of 5 stars0.01.00.04.30.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTGGFBitcoin Group 0.00N/AN/AN/AMEDPMedpace 2.21Hold$344.829.53% UpsideNRCNational Research 0.00N/AN/AN/ASRNESorrento Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MEDP, BTGGF, NRC, and SRNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025MEDPMedpaceBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Equal Weight$300.004/23/2025MEDPMedpaceTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$333.00 ➝ $300.004/23/2025MEDPMedpaceRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$340.00 ➝ $313.004/22/2025MEDPMedpaceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTGGFBitcoin GroupN/AN/AN/AN/AN/AN/AMEDPMedpace$2.11B4.29$14.05 per share22.41$26.56 per share11.85NRCNational Research$143.06M2.38$1.32 per share11.31$1.36 per share10.99SRNESorrento Therapeutics$60.32M0.09N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTGGFBitcoin GroupN/AN/A0.00∞N/AN/AN/AN/AN/AMEDPMedpace$404.39M$13.1024.0323.055.6619.31%54.36%20.81%7/21/2025 (Confirmed)NRCNational Research$24.78M$1.0314.51∞N/A17.14%71.33%18.67%7/28/2025 (Estimated)SRNESorrento Therapeutics-$572.84MN/A0.00∞N/AN/AN/AN/AN/ALatest MEDP, BTGGF, NRC, and SRNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/21/2025Q2 2025MEDPMedpace$3.01N/AN/AN/A$537.70 millionN/A4/28/2025Q1 2025NRCNational ResearchN/A$0.25N/A$0.25N/A$33.55 million4/21/2025Q1 2025MEDPMedpace$3.06$3.67+$0.61$3.67$528.38 million$558.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTGGFBitcoin GroupN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/ANRCNational Research$0.483.21%N/A46.60%N/ASRNESorrento TherapeuticsN/AN/AN/AN/AN/ALatest MEDP, BTGGF, NRC, and SRNE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/25/2025NRCNational Researchquarterly$0.124.1%6/27/20256/27/20257/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTGGFBitcoin GroupN/AN/AN/AMEDPMedpaceN/A0.730.73NRCNational Research1.980.540.54SRNESorrento TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTGGFBitcoin GroupN/AMEDPMedpace77.98%NRCNational Research47.26%SRNESorrento Therapeutics0.02%Insider OwnershipCompanyInsider OwnershipBTGGFBitcoin GroupN/AMEDPMedpace20.30%NRCNational Research8.10%SRNESorrento Therapeutics2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTGGFBitcoin Group35386.49 millionN/ANot OptionableMEDPMedpace5,90028.74 million22.91 millionOptionableNRCNational Research49022.78 million20.94 millionOptionableSRNESorrento Therapeutics800551.28 million536.95 millionNo DataMEDP, BTGGF, NRC, and SRNE HeadlinesRecent News About These CompaniesSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comSRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comSorrento Shareholders Lose Discovery Bid Over Judge RelationshipMarch 28, 2025 | news.bloomberglaw.comNScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comDSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel InfillsOctober 24, 2024 | newsfilecorp.comNSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Resources to Sell Three Newfoundland Properties to Gold HunterMay 29, 2024 | newsfilecorp.comNSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified PersonMay 8, 2024 | newsfilecorp.comNDSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh RailingMay 1, 2024 | newsfilecorp.comNSorrento Therapeutics Inc SRNEApril 26, 2024 | morningstar.comMSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Therapeutics Wins Appeal Over Covid Treatment RemarksMarch 27, 2024 | news.bloomberglaw.comNSorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)March 12, 2024 | news.bloomberglaw.comNJudge Declines to Dismiss Sorrento Therapeutics Bankruptcy CaseMarch 12, 2024 | wsj.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | tmcnet.comVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.February 27, 2024 | businesswire.comSorrento TherapeuticsFebruary 7, 2024 | pharmaphorum.comP5 Sanders Cove, Sorrento WA 6020January 18, 2024 | domain.com.auDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEDP, BTGGF, NRC, and SRNE Company DescriptionsBitcoin Group OTCMKTS:BTGGF$63.22 0.00 (0.00%) As of 07/15/2025Bitcoin Group SE, an investment holding company, engages in the cryptocurrency and blockchain businesses worldwide. The company operates a trading platform for the digital currency bitcoin under the Bitcoin.de. It also provides financial services. The company was founded in 2008 and is based in Herford, Germany. Bitcoin Group SE is a subsidiary of Priority AG.Medpace NASDAQ:MEDP$314.83 +2.12 (+0.68%) Closing price 04:00 PM EasternExtended Trading$315.15 +0.32 (+0.10%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.National Research NASDAQ:NRC$14.95 -0.15 (-0.99%) Closing price 04:00 PM EasternExtended Trading$14.94 -0.01 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.Sorrento Therapeutics NASDAQ:SRNE$0.0097 +0.01 (+592.86%) As of 03:55 PM EasternSorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.